We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+29.04%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$922M
AUM Growth
+$242M
Cap. Flow
+$283M
Cap. Flow %
30.74%
Top 10 Hldgs %
73.15%
Holding
32
New
7
Increased
7
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$176M
2
CGEM icon
Cullinan Oncology
CGEM
+$47.7M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$34.5M
4
PHVS icon
Pharvaris
PHVS
+$28.4M
5
VTGN icon
VistaGen Therapeutics
VTGN
+$15.4M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$19M
2
ALT icon
Altimmune
ALT
+$16.2M
3
SURF
Surface Oncology, Inc. Common Stock
SURF
+$13.3M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$11.8M
5
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$9.39M

Sector Composition

Rank Sector Weight
1 Healthcare 89.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRY icon
26
ARS Pharmaceuticals
SPRY
$509M
$3.71M 0.4%
85,000
-65,000
-43% -$3.08M
TSHA icon
27
Taysha Gene Therapies
TSHA
$1.68B
$2.45M 0.27%
120,649
+12,667
+12% +$343K
VRDN icon
28
Viridian Therapeutics
VRDN
$2.09B
$326K 0.04%
19,495
– –
BCAB icon
29
BioAtla
BCAB
$5.46M
– –
-2,000
Closed -$3.4M
GRTX
30
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-917,860
Closed -$9.39M
SURF
31
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-1,442,895
Closed -$13.3M
FPRX
32
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-245,122
Closed -$4.17M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q1 2021 Portfolio in Review

As of Q1 2021, VR Adviser held 32 positions worth $922M, up 36% from $680M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

VR Adviser deployed $283M of net new capital in Q1 2021, opening 7 new positions and adding to 7 existing holdings. Its largest new stake was Instil Bio: 343,254 shares worth $172M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $19M trimmed.

  • VR Adviser's largest Q1 2021 buy was Instil Bio: 343,254 shares worth $172M.
  • VR Adviser added most to Aclaris Therapeutics in Q1 2021, an estimated $34.5M increase.
  • VR Adviser's biggest Q1 2021 reduction was Keros Therapeutics, cutting an estimated $19M.
  • VR Adviser fully exited Surface Oncology, Inc. Common Stock in Q1 2021, selling an estimated $13.3M.
  • VR Adviser's ten largest holdings make up 73% of its $922M portfolio in Q1 2021.
  • VR Adviser opened 7 new positions and closed 4 in Q1 2021.
  • VR Adviser's portfolio value rose 36% quarter-over-quarter to $922M.

Based on VR Adviser's 13F filing for Q1 2021, filed 14 May 2021.